<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="49483"><DrugName>tetrazolium violet, Lan-Jin Corp</DrugName><DrugSynonyms><Name><Value>Tetrazolium violet</Value></Name><Name><Value>TV, Lan-Jin Corp</Value></Name><Name><Value>tetrazolium violet, Lan-Jin Corp</Value></Name><Name><Value>1719-71-7</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1069185">Shandong Lanjin Pharmaceuticals Co Ltd</CompanyOriginator><CompaniesSecondary><Company id="1069185">Shandong Lanjin Pharmaceuticals Co Ltd</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1069185" type="Company"><TargetEntity id="5035524918" type="organizationId">Shandong Lanjin Pharmaceuticals Co Ltd</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1545" type="Action"><TargetEntity id="4644" type="Mechanism">Anti-PD-L1/ VISTA Immune Checkpoint</TargetEntity><TargetEntity id="4426" type="Mechanism">Immune Checkpoint Inhibitors</TargetEntity><TargetEntity id="1937" type="Mechanism">Anti-Tumor Associated Glycoprotein 72 (TAG-72)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsSecondary><Action id="5725">Chemosensitizer</Action><Action id="59620">Unspecified drug target</Action><Action id="1545">Anticancer</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2015-06-11T14:13:30.000Z</LastModificationDate><ChangeDateLast>2013-03-11T00:00:00.000Z</ChangeDateLast><AddedDate>2004-04-05T17:27:31.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;As no development has been reported for some time, this program is assumed to be discontinued.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1069185"&gt;Lan-Jin Corp&lt;/ulink&gt; was investigating tetrazolium violet (TV), a centrosomal crystallizing agent, as a potential chemosensitizer and anticancer agent [&lt;ulink linkType="reference" linkID="530184"&gt;530184&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2004, preclinical data on TV were presented at the 95th AACR meeting in Orlando, FL. Rats with 1-week established subcutaneous 9L gliosarcoma were treated with intralesionally implanted TV at 3, 6 and 9 mg/kg. The tumor growth inhibition measured 10 days after drug implantation was 48, 86 and 88%, respectively, compared to controls. In in vitro studies, TV at 10 microg/ml alone was effective in inhibiting tumor cell growth. When used in combination, TV at 10 microg/ml significantly enhanced the sensitization of tumor cells to BCNU (10 microg/ml), ACNU (10 microg/ml) and cisplatin (20 microg/ml). TV at 40 microg/ml formed visible crystals on the centrosome 4 h post drug administration, which was referenced to the centrosome seen with electronic and immunofluorescent microscopes. Among the tested tumor cell types, 9L gliosarcoma and CNS-1 were most sensitive to TV [&lt;ulink linkType="reference" linkID="530184"&gt;530184&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;US-06376525, covering a method and composition for treating cancer using cellular organelle crystallizing agents, has been granted.&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1069185">Shandong Lanjin Pharmaceuticals Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-03-02T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1069185">Shandong Lanjin Pharmaceuticals Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2003-07-11T00:00:00.000Z</StatusDate><Source id="530184" type="SERIAL"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>c1ccc(cc1)c2nn([n+](n2)c3cccc4c3cccc4)c5ccccc5.[Cl-]</Smiles></StructureSmiles><hasSWOTs>N</hasSWOTs></drugRecordOutput>